---
title: "药物敏感性筛选，快来试试pRRophetic oncoPredict+细胞系实验+ Beyondcell"
date: 2024-05-08T02:14:44Z
draft: ["false"]
tags: [
  "fetched",
  "生信人"
]
categories: ["Acdemic"]
---
药物敏感性筛选，快来试试pRRophetic oncoPredict+细胞系实验+ Beyondcell by 生信人
------
<div><p><span>肿瘤异质性导致不同患者采用相同药物方案治疗，效果差异巨大。如何预测个体对不同药物的治疗响应和筛选新的治疗药物？我们可以试试这篇2022年在<span><strong>cell discovery</strong></span>发表的<span>Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas</span></span><span><sup><span>[1]</span></sup></span><span>的方案--<span>pRRophetic/oncoPredict+细胞系实验+ Beyondcell</span></span></p><p><span><br></span></p><p><span>小肠腺癌(Small bowel adenocarcinomas;SBAs)是一种罕见的高死亡率恶性肿瘤，其分子特征在很大程度上仍未被探索。可用数据有限，结直肠癌的研究的推断被用作SBA治疗的主要参考。基于目前缺乏针对SBA的特异性药物的情况，本文采用<span>pRRophetic/ oncoPredict + Beyondcell + 细胞系实验来研究药物敏感性</span>，根据这些预测和验证的候选药物可能潜在地使SBA患者受益。</span></p><p><span>               </span></p><p><img data-galleryid="" data-ratio="0.375" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrdiaHtjam1YaCkPY9vcfiaGCQvtMia51lgQibaPVicDUymkOJj25tOq9jTuA/640?wx_fmt=png" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrdiaHtjam1YaCkPY9vcfiaGCQvtMia51lgQibaPVicDUymkOJj25tOq9jTuA/640?wx_fmt=png"></p><p><span>          <br></span></p><p><span>说明：本文对来自12名SBA患者的肿瘤样本进行了单细胞RNA测序（改进的高精度STRT法和10x），并预测了SBA的候选药物。确定了四种常见的恶性细胞亚型，它们具有不同的特征，包括细胞周期程序、线粒体程序、代谢程序和上皮-间质转化(EMT)程序。揭示了四种恶性细胞亚型的进展关系，从细胞周期程序开始，经过线粒体程序，然后进入代谢程序或EMT程序。重要的是，研究发现配体-受体相互作用对在EMT程序恶性细胞和高度耗竭的CD8+ T细胞中特异性富集，这表明具有EMT特征的癌细胞亚群可能对T细胞的耗竭贡献最大。本文还发现，十二指肠SBA亚型的分子特征更类似于胃癌，而空肠SBA亚型的分子特征更类似于结直肠癌。特别是，根据<span>SBA恶性细胞与正常上皮细胞之间的差异基因表达特征预测了SBA的特异性药物</span>，并验证了volasertib和tozasertib对SBA癌细胞的抑制作用比相同浓度的SBA常规药物<span>更强</span>，这为SBA的治疗提供了新的线索。总之，本研究提供了SBA中肿瘤细胞和肿瘤微环境细胞的分子特征蓝图，并揭示了其临床治疗的潜在靶点和候选药物。</span></p><p><span>          <br></span></p><p><span>下面我们来看一下作者是怎么进行药物敏感性相关研究的。</span></p><p><br></p><p><span><strong><span>pRRophetic/oncoPredict筛选敏感性药物</span></strong></span></p><p><span><strong><span><br></span></strong></span></p><p><img data-galleryid="" data-ratio="0.8777777777777778" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrzNIZCGrIIA9tIOdEia3R3yLicSKp5AyKee7dnazJPm15g1IIbJaqC1jw/640?wx_fmt=png" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrzNIZCGrIIA9tIOdEia3R3yLicSKp5AyKee7dnazJPm15g1IIbJaqC1jw/640?wx_fmt=png"></p><p><span>图1 药物预测的简单工作流程</span></p><p><span><br></span></p><p><span>说明：oncoPredic（2021）</span><span><sup><span>[2]</span></sup></span><span>是pRRophetic</span><span><sup><span>[3]</span></sup></span><span>（2014）升级版，实现更快，提供更新的CTRP和GDSC筛选数据，并允许增加用户自定义。</span></p><p><span>      </span><br></p><p><span>为了确定更具体的SBA候选药物，本研究使用<span>pRRophetic (version 0.5)</span> 基于岭回归的方法来预测SBA的潜在药物反应IC50 AUC值(图1)。以CCLE的细胞系转录组学数据和CTRP、PRISM、GDSC1和GDSC2的药物反应数据作为训练集，训练集包括2521种药物和1969种细胞系的数据。将STRT scRNA-seq数据上皮细胞中的恶性和正常上皮细胞随机分为50组，以平均表达值作为伪大样本。使用calcPhenotype函数计算每种对应药物的IC50 AUC值，并根据以下标准选择SBA的潜在候选药物:调整后的P值&lt; 0.05 (t检验下)，肿瘤细胞相对于正常细胞的log2FC值&lt; - 0.1，与肿瘤评分的相关性&lt; - 0.5。共获得14种预测药物，其中1种来自CTRP数据库，2种来自GDSC1数据库，其余来自PRISM数据库(图2)。</span></p><p><span><br></span></p><p><img data-galleryid="" data-ratio="0.9953703703703703" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnr9ABlMs6gXTbfMdhiagzLeliaGMTIZ5ZAgCYSCkrByIxFIRq9mh0vnqxw/640?wx_fmt=png" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnr9ABlMs6gXTbfMdhiagzLeliaGMTIZ5ZAgCYSCkrByIxFIRq9mh0vnqxw/640?wx_fmt=png"></p><p><span>图2 散点图。横坐标为肿瘤样本与正常样本的log2FC 差异倍数，纵坐标表示根据每种药物的预测IC50 AUC值与肿瘤评分的相关性。选择有标签的药物作为候选药物。</span></p><p><span>          <br></span></p><p><span>在14种预测药物中，选取了filanesib、mocetinostat、tozasertib 和volasertib 4种来验证对SBA的抑制作用。filanesib是一种激酶纺锤体蛋白(KIF11)抑制剂，最近被提议用于癌症治疗，特别是多发性骨髓瘤。mocetinostat是一种组蛋白去乙酰化酶(HDAC)抑制剂，正在进行临床试验，用于治疗许多癌症，包括滤泡性淋巴瘤、霍奇金淋巴瘤和急性髓性白血病。Tozasertib是一种pan-Aurora抑制剂，主要针对Aurora A。Volasertib是PLK1 (pololike kinase 1)蛋白的实验性小分子抑制剂，被开发用作抗癌剂。挑选这些候选药物的标准如下。首先，这些选择的候选药物至少在其他癌症类型中处于临床特征的II期，这意味着毒副作用对癌症患者是可以接受的，并且具有安全性和剂量相关的研究数据。其次，这些药物相对容易获得。虽然这些基因的绝对表达水平相对较低，但与邻近的正常组织相比，这四种选定药物的靶点在肿瘤组织中表达更高(图3)。</span></p><p><span><br></span></p><p><img data-galleryid="" data-ratio="0.3490740740740741" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrU7C6kDguP1XZzqlj11pzmcwaA19V3GfMQh4sgbxWUzdyyNdOcr1FyA/640?wx_fmt=png" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrU7C6kDguP1XZzqlj11pzmcwaA19V3GfMQh4sgbxWUzdyyNdOcr1FyA/640?wx_fmt=png"></p><p><span>图3 箱线图显示四种选定药物在整合数据集中靶基因的表达情况，其中“ns”表示无显著性，P值采用t检验计算</span></p><p><br></p><p><span><strong><span>细胞系实验进一步验证和筛选敏感性药物</span></strong></span></p><p><span>为了评估候选药物对SBA的抑制作用，筛选了来自十二指肠腺癌的HUTU-80细胞系， filanesib、mocecinostat、tozasertib和volasertib这四种药物以及两种SBA常规药物oxaliplatin 和 irinotecan为对照（图4）。</span></p><p><span><br></span></p><p><img data-galleryid="" data-ratio="0.6222222222222222" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnr5snwo0VqID9JPlhp7XfscoExdlJ6ibW6ym2IKmjhTCg2I4iadf5QEY5Q/640?wx_fmt=png" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnr5snwo0VqID9JPlhp7XfscoExdlJ6ibW6ym2IKmjhTCg2I4iadf5QEY5Q/640?wx_fmt=png"></p><p><span>图4 用指定抑制剂处理HUTU-80细胞的细胞存活曲线，剂量从0到100 μM递增。数据以均数±SD表示。</span></p><p><span><br></span></p><p><img data-galleryid="" data-ratio="2.221631205673759" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrbYSxhZF3KhJ24OS9XJ8ibhk3MLadEpF2icbdqIRGr04WImsYyMX7Pia5w/640?wx_fmt=png" data-type="png" data-w="564" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrbYSxhZF3KhJ24OS9XJ8ibhk3MLadEpF2icbdqIRGr04WImsYyMX7Pia5w/640?wx_fmt=png"></p><p><span>图5 箱线图表示在所选药物在0.1μM浓度下在HUTU-80细胞系中的相对活力，其中“ns”表示无显著性，P值采用t检验计算。</span></p><p><br></p><p><span>尤其在0.1μM浓度下，volasertib 和tozasertib的抑制作用显著高于oxaliplatin 和 irinotecan (图4，图5)。虽然moncetinostat在0.1μM浓度下也有类似的抑制作用，但在较高浓度下并没有表现出更强的抑制作用。同时进行了细胞活力测定和剂量反应分析，以检测这些药物的抑制作用。<span>在HUTU-80细胞中，volasertib和tozasertib具有最明显的抑制作用</span>，而moncetinostat和silanesib与oxaliplatin 和 irinotecan相比，抑制作用没有显著差异。volasertib和tozasertib均靶向细胞周期以抑制细胞分裂。</span></p><p><span><br></span></p><p><span><strong><span>Beyondcell查看药物敏感性的异质性</span></strong></span></p><p><span>说明：Beyondcell</span><span><sup><span>[4]</span></sup></span><span>用于识别单细胞RNA-seq数据中具有不同药物反应的肿瘤细胞亚群，并提出癌症特异性治疗方案。计算药物特征集合中的富集分数，描绘细胞群体内的治疗簇。确定细胞群之间的治疗差异，并生成基于敏感性的优先排序，以指导药物选择。</span></p><p><span>                 </span></p><p><span>为了阐明筛选药物对SBA单独恶性细胞的敏感性，本研究在STRT scRNA-seq数据集中计算了tozasertib和irinotecan对单独上皮细胞的药物反应。从Beyondcell建立的数据库中通过药物诱导的转录变化计算UMAP嵌入，并根据恶性细胞和正常上皮细胞划分簇，这类似于基于基因表达的簇(图6)。</span></p><p><span>          <br></span></p><p><img data-galleryid="" data-ratio="0.7228661749209695" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrgrPGt4GXibTLkRHrelzLrIiauRVcv8ia7Xzd7BVpalAz9fg9saic9achJg/640?wx_fmt=png" data-type="png" data-w="949" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrgrPGt4GXibTLkRHrelzLrIiauRVcv8ia7Xzd7BVpalAz9fg9saic9achJg/640?wx_fmt=png"></p><p><span>图6 UMAP图。根据Beyondcell建立的数据库中药物诱导的转录变化确定了恶性细胞和正常上皮细胞的差异。</span></p><p><span><br></span></p><p><span>Tozasertib在Beyondcell的内置数据集中有三个相似的相关特征。tozasertib的这些特征的高、低药敏评分与恶性上皮细胞和正常上皮细胞的分类相似，这与预测结果一致，证明了SBA在恶性细胞中的药物特异性(图7)。irinotecan仅对部分恶性细胞表现出高易感，而tozasertib对几乎所有恶性细胞都表现出高易感，这可能解释了为什么tozasertib比irinotecan的抑制作用更高(图7)。irinotecan是治疗肠癌的常规药物之一，而irinotecan在SBA中药物敏感性的异质性，提示SBA急需更特异的药物。tozasertib的高敏感性和特异性可能为SBA的治疗提供新的线索。</span></p><p><span><br></span></p><p><img data-galleryid="" data-ratio="0.39814814814814814" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrn9iaKmCicBbiablT4wevEuX3mpeO4dqVnqoI3oeOsJXesSE5dq7nOLvVw/640?wx_fmt=png" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrn9iaKmCicBbiablT4wevEuX3mpeO4dqVnqoI3oeOsJXesSE5dq7nOLvVw/640?wx_fmt=png"></p><p><span>图7 基于Beyondcell的STRT scRNA-seq数据集评估tozasertib和irinotecan在单细胞中的药物敏感性。</span></p><p><span>          <br></span></p><p><span><strong><span> 小结：</span></strong></span></p><p><span>这篇文章中首先使用pRRophetic/oncoPredict筛选了14种候选药物，进一步选择4种药物进行细胞系实验并获得2种候选药物效果优于SBA常规药物，最后使用 Beyondcell来分析药物敏感性的异质性，进一步评估药物敏感性。类比一下，其他癌种尤其是稀有亚型，也可以通过这种分析方法获得候选药物来改善治疗。</span></p><p><span><br></span></p><p><span><strong><span>药物敏感性相关热点<br></span></strong></span></p><p><span><strong><span>扫码咨询</span></strong></span></p><p><span><strong><span><img data-ratio="1" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrDWt4rtI0PvfQbnfVhhGePpTvtsN1BfEZokBy5W5OIib9CYdzQm25Z6A/640?wx_fmt=jpeg" data-type="jpeg" data-w="150" src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrDWt4rtI0PvfQbnfVhhGePpTvtsN1BfEZokBy5W5OIib9CYdzQm25Z6A/640?wx_fmt=jpeg"></span></strong></span></p><p><br></p><p><span>【注】</span><br></p><p><span>pRRophetic：</span><span>https://github.com/paulgeeleher/pRRophetic</span></p><p><span>oncoPredic：</span><span>https://github.com/maese005/oncoPredict</span></p><p><span><span>Beyondcell：</span></span><span>https://github.com/cnio-bu/beyondcell</span><span>               </span></p><p><br></p><p><span><strong><span>References:</span></strong></span></p><p><span>[1].Yang, J., et al., Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas. Cell Discovery, 2022. 8(1).</span></p><p><span>[2].Maeser, D., R.F. Gruener and R.S. Huang, oncoPredict: an R package for predictingin vivo  or cancer patient drug response and biomarkers from cell line screening data. Briefings in Bioinformatics, 2021. 22(6).</span></p><p><span>[3].Paul, G., C. Nancy and S.H. R, pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE, 2017. 9(9).</span></p><p><span>[4].Fustero-Torre, C., et al., Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data. Genome Medicine, 2021. 13(1).</span></p><p><span><br></span></p><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section><section><section powered-by="xiumi.us"><p><strong>往期热点 </strong><span><strong><span>（点击标题跳转）</span></strong></span></p></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>01</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>线粒体质量控制</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>02</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>孟德尔随机化</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>03</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>成纤维细胞（CAFs）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>04</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>单细胞空间转录组</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>05</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>肿瘤相关巨噬细胞（TAM）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>06</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>细胞死亡</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>07</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>耐药</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><img data-ratio="1" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrFkWyNial5siaXWStuIXg17P7NPVCmspxC6aH5fmUz4CO0KbOI5dTu1cQ/640?wx_fmt=png" data-type="png" data-w="692" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjUB1y6ksjcuWFLIfveebrnrFkWyNial5siaXWStuIXg17P7NPVCmspxC6aH5fmUz4CO0KbOI5dTu1cQ/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><section><p>更多精彩生信知识和技术分享</p><p>欢迎添加微信</p></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><span>图文排版｜CY</span></p><p>文章转载请联系 | 15510012760（微信）</p><p>广告商务合作 | 18501253903（微信）</p></section><section powered-by="xiumi.us"><p><br></p></section></section></section><p powered-by="xiumi.us"><br></p></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/WiEPqsBafUDbVIkv_3F5Kg",target="_blank" rel="noopener noreferrer">原文链接</a>
